Clinical Trial Update: A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) [Phase 3]

View source ↗

Summary

Phase 3 trial of vericiguat in participants with heart failure with reduced ejection fraction (HFrEF) has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2020-06-29